
iShares II PLC - iShares UK Foreign Focus UCITS ETF Accum- GBP
iShares II PLC - iShares UK Foreign Focus UCITS ETF Accum- GBP (GB:KFOR) Price & Chart
GB:KFOR ETF Chart & Stats
- Day’s Range
- GBP 516.10 - GBP 519.40
- 52-Week Range
- GBP 489.20 - GBP 529.80
- Previous Close
- GBP 517.42
- Volume
- 6
- Average Volume (3M)
- 181
- AUM
- 2.59M
- NAV
- 5.10
- Expense Ratio
- 0.28%
- Holdings Count
- 169
- Beta
- 1.06
- Inception Date
- Apr 23, 2026
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 500,000
- Standard Deviation
- N/A
ETF Overview
iShares II PLC - iShares UK Foreign Focus UCITS ETF Accum- GBP
iShares II PLC – iShares UK Foreign Focus UCITS ETF (Ticker: GB:KFOR) is an accumulating, GBP‑denominated UCITS ETF that seeks to track the STOXX UK Foreign Focus Index, offering investors broad exposure to the UK equity market with a distinct foreign‑revenue tilt. Categorised under Size & Style with a Total Market focus in a broad‑based niche, the fund provides diversified access across market capitalisations and sectors of UK‑listed companies that derive a meaningful portion of their sales or earnings from overseas. By mirroring the benchmark, the ETF aims to deliver a return that reflects both capital growth and the income generated by its constituent companies, while the accumulating share class automatically reinvests dividends to compound returns over time. The strategy is suited to investors who want core UK equity exposure but with reduced home‑bias—capturing international economic exposure through domestically listed firms. As a UCITS vehicle, it follows European regulatory standards for diversification and investor protection, making it a straightforward building block for portfolios seeking long‑term growth with a global revenue orientation via the UK market.
- Asset Class
- Equity
- Region
- Global
- Issuer
- iShares
- Index Tracked
- STOXX UK Foreign Focus Index - GBP - Benchmark TR Net
- Ticker Symbol
- GB:KFOR
GB:KFOR ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s GRACE-DE study, officially titled “Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating




GB:KFOR ETF FAQ
What was GB:KFOR’s price range in the past 12 months?
What is the AUM of GB:KFOR?
Is GB:KFOR overvalued?
How many shares outstanding does GB:KFOR have?
GB:KFOR ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| HSBAHsbc Holdings Plc (UK) | 10.26% |
| AZNAstraZeneca plc | 9.70% |
| SHELLShell plc (UK) | 9.26% |
| RRRolls-Royce Holdings | 5.00% |
| ULVRUnilever Plc (UK) | 4.90% |
| BATSBritish American Tobacco (UK) | 4.46% |
| BPBP p.l.c. | 4.24% |
| GSKGlaxoSmithKline plc (UK) | 3.47% |
| NGNational Grid (Uk) | 2.99% |
| RIORio Tinto (LSE:RIO) | 2.93% |
| Total | 57.21% |









